# Fungal Infections Diagnosis Market worth $3.35 billion by 2030 - Exclusive Report by 360iResearch

The Global Fungal Infections Diagnosis Market to grow from USD 1.96 billion in 2022 to USD 3.35 billion by 2030, at a CAGR of 6.94%.

PUNE, MAHARASHTRA, INDIA, November 16, 2023 / EINPresswire.com/ -- The "Fungal Infections Diagnosis Market by Type (Endemic Fungal Infections, Opportunistic Fungal Infections, Subcutaneous Fungal Infections), Diagnostic Method (Antigen Testing, Dermatological Examination, Histopathology), End-User - Global Forecast 2023-2030" report has been added to 360iResearch.com's offering.

Fungal Infections Diagnosis Market - Exclusive Report by 360iResearch

The Global Fungal Infections Diagnosis Market to grow from USD 1.96 billion in 2022 to USD 3.35 billion by 2030, at a CAGR of 6.94%.

Request a Free Sample Report @ https://www.360iresearch.com/library/intelligence/fungal-infections-diagnosis?utm_source=einpresswire&utm_medium=referral&utm_campaign=sample

Fungal infections, or mycosis, refer to infections or diseases caused by a fungus species (yeast or mold). Fungal infections are most commonly observed on the skin or nails, but fungi can also cause infections in the mouth, throat, lungs, and urinary tract. Fungal infections come in different forms, such as ringworm athlete's foot, toenail fungus, yeast infections, and jock itch. Diagnosis of fungal infection primarily relies on methodologies such as microscopic examination of clinical samples, histopathology, culture, X-rays, MRI, or CT imaging. The rising incidences of fungal infections across the world have led to a surge in demand for effective disease detection technologies. Furthermore, government initiatives promoting awareness of fungal infection

management and efforts to expand access to healthcare facilities have led to rising adoption of fungal infection diagnosis. However, the complexity of molecular and genetic fungal infection diagnosis and the lack of skilled medical and clinical personnel impeded the growth of fungal infection diagnosis solutions. Additionally, inaccurate or inconsistent diagnosis results and stringent regulations pertaining to product approval also pose challenges for fungal infection diagnosis devices, solutions, and services. However, major players are rapidly expanding investments in R&D initiatives to improve the capabilities and accuracy of diagnosis technologies. Advances in imaging technologies enhanced digital solutions for remote diagnosis and the introduction of artificial intelligence in rapid diagnostic techniques present opportunities for growth.

End-user: Expanding healthcare expenditure leading to growth and significance of hospitals for fungal infection diagnosis
Hospitals remain the dominant end-users for fungal infection diagnoses. With their complex internal structures, extensive facilities, trained personnel, and round-the-clock services, hospitals cater to the growing need for fungal disease diagnosis. The need for routine health check-ups and the critical role that early detection plays in achieving successful treatment outcomes has driven the significance of hospitals for fungal infection diagnosis. Point-of-care (PoC) settings, such as clinics and urgent care centers, are pivotal spaces for diagnosing fungal infections. The PoC settings work towards quick and appropriate diagnosis, facilitating effective treatment strategies. Research Institutions such as universities, colleges, and pharmaceutical companies play a crucial role in diagnosing fungal infections. They enhance existing methods, explore innovative techniques, and establish benchmarks in the diagnosis of fungal infections. Specialty clinics cater to specific patient groups and target niche patient needs compared to general care settings, thereby necessitating a different set of diagnosis tools and techniques.

Diagnostic Method: Advancements in cellular and molecular biology leading to the adoption of molecular diagnostics for infection detection
Antigen tests refer to procedures that measure fungal cell wall molecules (mainly carbohydrates) that are shed into the body fluids of the patient. The most frequently used methods are latex agglutination and enzyme immunoassay (EIA) for the detection of fungal species. Dermatological examinations are critical in diagnosing dermatophytosis and other skin-related fungal infections. They may involve visual inspections, skin scrapings, or biopsies. Histopathology involves examining tissues for microscopic fungal elements. The method is particularly useful for identifying invasive and systemic fungal infections that aren't easily observable. Histopathologic diagnosis can provide a description of the fungus and can provide information regarding the presence or absence of tissue invasion and the host reaction to the infection. Microbiological culture can help identify and classify based on visual morphological features such as colony morphology and color. Molecular diagnostics, such as PCR (Polymerase Chain Reaction), provides sensitive and specific detection of fungal DNA or RNA. This method can be especially useful for fastidious organisms or when culture isn't practical. The serological tests are performed to demonstrate the presence of antigen or antibody in the body fluids of the patient. The immune response that results from exposure to cell wall, cytoplasmic, or extracellular fungal

antigen during infection can be used for diagnosis.

Type: Growing incidences of opportunistic fungal infections due to weakened immune system in patients

Endemic fungal infections or mycoses are a group of diseases caused by diverse fungi that share common characteristics. These infections are caused by fungi that occupy a specific etiologic niche in the environment, are dimorphic in nature, and are able to produce infection in healthy hosts. These infections can be caused by Coccidioides species, Histoplasma capsulatum, Blastomyces species, and Paracoccidioides species. Opportunistic fungal infections refer to diseases or infections affecting immune-compromised individuals, many of which are part of the normal upper respiratory tract flora. Such infections can include mucocutaneous candidiasis, pneumocystosis, thrush, histoplasmosis, candida, and cryptococcosis. Subcutaneous fungal infections are chronic, localized infections of the skin caused by a heterogeneous group of fungi that infect the skin, subcutaneous tissue, and, in some cases, the underlying tissues and organs. Sporotrichosis, mycetoma, and chromoblastomycosis are more common subcutaneous mycoses. Superficial fungal infections are benign infections of the skin, scalp, and nails caused by Candida albicans or dermatophytes. Systemic fungal infections refer to infections that affect the skin and other organs, such as the lungs, eyes, liver, and brain, and typically occur in immunocompromised hosts.

Regional Insights:

The Americas, specifically the US and Canada, present a mature region for fungal infections diagnostic tools, attributable to the increased public consciousness about fungal infections. Americas is characterized by the presence of robust research institutions and medical infrastructure, contributing to the timely and accurate diagnosis of various fungal infections. The technological advancements in diagnostic techniques, including PCR and next-generation sequencing, have accelerated the diagnosis process, improved accuracy, and reduced the potential risk of fatality in the Americas region. In Europe, the spread of fungal infections shows a significant increase, mostly attributed to the elderly population and those with immunosuppressive conditions. There is a rising demand for effective diagnostic tools driven by increased awareness about fungal infections. European region exhibits a rise in travel and migration, which contributes to the introduction and spread of various fungal pathogens. Medical practitioners, therefore, adopt innovative fungal infection diagnostics to manage the potential outbreaks in this high-risk environment effectively. Significant investments in R&D and a growing number of start-ups characterize this region. Asia-Pacific (APAC) region is witnessing an upsurge in the incidence of fungal infections, primarily due to escalating population density and climatic conditions that favor fungal growth. The APAC region, chiefly China, Japan, and India, shows immense potential due to escalating healthcare expenditure and a surge in patient awareness.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Fungal Infections Diagnosis Market. It

provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in the Fungal Infections Diagnosis Market. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

Key Company Profiles:

The report delves into recent significant developments in the Fungal Infections Diagnosis Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alexion Pharmaceuticals, Inc., Amgen Inc., Associates of Cape COD, Inc. by Seikagaku Group company, Astellas Pharma Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BioMérieux SA, Bruker Corporation, Danaher Corporation, Eli Lilly and Company, ELITech Group, Eurofins Viracor, LLC, F. Hoffmann-La Roche AG, Hologic, Inc., Immununexpress Inc., IMMY, InBios International, Inc., Laboratory Corporation of America Holdings, Merck KGaA, Norgen Biotek Corp., PerkinElmer, Inc., Polysciences, Inc., Qiagen N.V., Siemens Healthineers, Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..

Inquire Before Buying @ https://www.360iresearch.com/library/intelligence/fungal-infections-diagnosis?utm_source=einpresswire&utm_medium=referral&utm_campaign=inquire

Market Segmentation & Coverage:

This research report categorizes the Fungal Infections Diagnosis Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Type, market is studied across Endemic Fungal Infections, Opportunistic Fungal Infections, Subcutaneous Fungal Infections, Superficial Fungal Infections, and Systemic Fungal Infections. The Opportunistic Fungal Infections is projected to witness significant market share during forecast period.

Based on Diagnostic Method, market is studied across Antigen Testing, Dermatological Examination, Histopathology, Microbiological Culture, Molecular Diagnostics, and Serology. The Antigen Testing is projected to witness significant market share during forecast period.

Based on End-User, market is studied across Hospitals, Point-of-Care Settings, Research Institutions, and Specialty Clinics. The Hospitals is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 41.59% in 2022, followed by Europe, Middle East & Africa.

Key Topics Covered:

1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
6. Fungal Infections Diagnosis Market, by Type
7. Fungal Infections Diagnosis Market, by Diagnostic Method
8. Fungal Infections Diagnosis Market, by End-User
9. Americas Fungal Infections Diagnosis Market
10. Asia-Pacific Fungal Infections Diagnosis Market
11. Europe, Middle East & Africa Fungal Infections Diagnosis Market
12. Competitive Landscape
13. Competitive Portfolio
14. Appendix

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D

activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Fungal Infections Diagnosis Market?
2. Which are the products/segments/applications/areas to invest in over the forecast period in the Fungal Infections Diagnosis Market?
3. What is the competitive strategic window for opportunities in the Fungal Infections Diagnosis Market?
4. What are the technology trends and regulatory frameworks in the Fungal Infections Diagnosis Market?
5. What is the market share of the leading vendors in the Fungal Infections Diagnosis Market?
6. What modes and strategic moves are considered suitable for entering the Fungal Infections Diagnosis Market?

Read More @ https://www.360iresearch.com/library/intelligence/fungal-infections-diagnosis?utm_source=einpresswire&utm_medium=referral&utm_campaign=analyst

Mr. Ketan Rohom
360iResearch
+ 1 530-264-8485
ketan@360iresearch.com

This press release can be viewed online at: https://www.einpresswire.com/article/669011723